[go: up one dir, main page]

WO1992011850A3 - Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence - Google Patents

Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence Download PDF

Info

Publication number
WO1992011850A3
WO1992011850A3 PCT/US1991/009786 US9109786W WO9211850A3 WO 1992011850 A3 WO1992011850 A3 WO 1992011850A3 US 9109786 W US9109786 W US 9109786W WO 9211850 A3 WO9211850 A3 WO 9211850A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neurodegeneration
inhibition
peptide
calpain inhibitors
Prior art date
Application number
PCT/US1991/009786
Other languages
English (en)
Other versions
WO1992011850A2 (fr
Inventor
Raymond T Bartus
David D Eveleth Jr
Gary S Lynch
James C Powers
Original Assignee
Cortex Pharma Inc
Georgia Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc, Georgia Tech Res Inst filed Critical Cortex Pharma Inc
Priority to AU91527/91A priority Critical patent/AU667463B2/en
Priority to JP4503767A priority patent/JPH06504061A/ja
Publication of WO1992011850A2 publication Critical patent/WO1992011850A2/fr
Publication of WO1992011850A3 publication Critical patent/WO1992011850A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés inhibiteurs de la calpaïne et également des compositions pharmaceutiques contenant lesdits composés inhibiteurs de la calpaïne. On peut utiliser lesdits composés dans le traitement d'une pathologie neurodégénérative chez l'homme. L'invention concerne également d'autres utilisations et des compositions pharmaceutiques contenant les composés inhibiteurs de la calpaïne, tels que des céto-amides peptidiques, des céto-acides peptidiques, et des céto-esters peptidiques.
PCT/US1991/009786 1990-12-28 1991-12-27 Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence WO1992011850A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU91527/91A AU667463B2 (en) 1990-12-28 1991-12-27 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
JP4503767A JPH06504061A (ja) 1990-12-28 1991-12-27 神経変性の治療および予防におけるカルパイン阻害剤の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63595290A 1990-12-28 1990-12-28
US635,952 1990-12-28

Publications (2)

Publication Number Publication Date
WO1992011850A2 WO1992011850A2 (fr) 1992-07-23
WO1992011850A3 true WO1992011850A3 (fr) 1992-09-03

Family

ID=24549781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/009786 WO1992011850A2 (fr) 1990-12-28 1991-12-27 Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence

Country Status (5)

Country Link
EP (1) EP0564552A1 (fr)
JP (1) JPH06504061A (fr)
AU (2) AU667463B2 (fr)
CA (1) CA2098609A1 (fr)
WO (1) WO1992011850A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078424B2 (en) 1998-06-03 2006-07-18 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
US5637589A (en) * 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5536639A (en) * 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US6319929B1 (en) 1994-04-29 2001-11-20 The University Of North Carolina At Chapel Hill Suksdorfin analogs, compositions thereof, and methods for making and using thereof
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2200964A1 (fr) * 1994-11-24 1996-05-30 Takashi Sohda Derives d'alpha-cetoamide utilises comme inhibiteurs de cathepsine l
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
US5827877A (en) 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
ES2293651T3 (es) * 1995-11-28 2008-03-16 Cephalon, Inc. Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
IL130124A0 (en) * 1996-12-11 2000-06-01 Basf Ag Ketobenzamides as calpain inhibitors
MY133063A (en) 1998-03-20 2007-10-31 Senju Pharma Co Pharmaceutical composition for prophylaxis and therapy of brain tissue impairment
KR20010042842A (ko) 1998-04-20 2001-05-25 스타르크, 카르크 칼파인 억제제로서 사용되는 헤테로고리 치환된 아미드
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
ATE264310T1 (de) 1998-04-20 2004-04-15 Abbott Gmbh & Co Kg Neue substituierte amide, deren herstellung und anwendung
CZ20004381A3 (cs) 1998-05-25 2001-09-12 Basf Aktiengesellschaft Nové heterocyklicky substituované amidy, jejich příprava a použití
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
WO2001046195A1 (fr) 1999-12-21 2001-06-28 Gpi Nil Holdings, Inc. Composes a base de derives d'hydantoïne, compositions pharmaceutiques, et modes d'utilisation
JP4298289B2 (ja) 2000-07-21 2009-07-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PL365695A1 (en) 2000-07-21 2005-01-10 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
FR2817867B1 (fr) * 2000-12-11 2006-06-30 Trophos Isocoumarines inhibitrices de la production de peptide amyloide, preparation, compositions les contenant et utilisations
DE10105040A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
WO2013082458A1 (fr) 2011-12-02 2013-06-06 The Regents Of The University Of California Solution de protection de reperfusion et ses utilisations
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
AU2015346371A1 (en) * 2014-11-11 2017-04-27 Western University Of Health Sciences Isoform-specific calpain inhibitors, methods of identification, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Annals of the New York Academy of Siences, volume 568, (New York, US) R.A. Nixon: "Calcium-activated neutral proteinases as regulators of cellular function", pages 198-208 *
Brain Research Contents, volume 530, no. 1, 15 October 1990, Elsevier Science Publishers B.V.; S. del Cerro et al.: "Development of hippocampal long-term potentiation is reduced by recently introduced calpain inhibitors", pages 91-95 *
Brain Research Contents, volume 532, no. 1/2, 5 November 1990, Elsevier Science Publishers B.V., A. Arai et al.: "Calpain inhibitors improve the recovery of synaptic transmission from hypoxia in hippocampal slices", pages 63-68, see the entire article, especially "results" *
Neurobiology of Aging, volume 11, no. 4, 1990, Pergamon Press plc., (US) E. Nilsson et al.: "Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue", pages 425-431, see the whole article, especially "Discussion" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078424B2 (en) 1998-06-03 2006-07-18 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres

Also Published As

Publication number Publication date
AU5590596A (en) 1996-08-22
JPH06504061A (ja) 1994-05-12
AU9152791A (en) 1992-08-17
WO1992011850A2 (fr) 1992-07-23
AU667463B2 (en) 1996-03-28
EP0564552A1 (fr) 1993-10-13
CA2098609A1 (fr) 1992-06-29

Similar Documents

Publication Publication Date Title
WO1992011850A3 (fr) Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence
EP1210941A3 (fr) Compositions pharmaceutiques contenant le ritonavir (ABT-538) associé à l'indinavir (MK-639) et son utilisation pour le traitement du SIDA
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
CA2220055A1 (fr) Dipeptides favorisant la secretion de l'hormone de croissance
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
HUP9904221A3 (en) Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia for producing pharmaceutical compositions
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
AU1402895A (en) Use of pla2 inhibitors as treatment for alzheimer's disease
DE69315257D1 (de) Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen
AU2106592A (en) Novel orally-active elastase inhibitors
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CZ58795A3 (en) Sulfonamides acting as inhibitors of hiv-aspartyl-protease, pharmaceutical compositions containing thereof and their use for prevention and treating hiv infection
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
AU1463992A (en) Methods and pharmaceutical compositions for inhibiting protease from human immunodeficiency virus
WO1996022305A3 (fr) Peptides modifies
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
PL313078A1 (en) Novel bis-naphtalimides for use in treating carcinoma
GB9907571D0 (en) Compounds
CA2279184A1 (fr) Compositions pharmaceutiques contenant de l'ibuprofene et de la domperidone pour le traitement de la migraine
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
NO934832D0 (no) Farmasoeytisk sammensetning for forhindring eller behandling av ar terioscherose
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PAT.BUL.19/92 UNDER PUBLISHED REPLACE "A1" BY "A2"

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

EX32 Extension under rule 32 effected after completion of technical preparation for international publication
WWE Wipo information: entry into national phase

Ref document number: 2098609

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992902904

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992902904

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992902904

Country of ref document: EP